Redhill Biopharma
RDHL
40 hedge funds and large institutions have $1.46M invested in Redhill Biopharma in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 9 closing their positions.
232% more call options, than puts
Call options by funds: $63K | Put options by funds: $19K
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
0% less ownership
Funds ownership: 0% → 0% (-0%)
9% less funds holding
Funds holding: 44 → 40 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
62% less capital invested
Capital invested by funds: $3.89M → $1.46M (-$2.43M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$219K |
| 2 |
Morgan Stanley
New York
|
+$212K |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$71.4K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$59.2K |
| 5 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$32.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.17M |
| 2 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$705K |
| 3 |
State Street
Boston,
Massachusetts
|
-$45K |
| 4 |
AC
Annandale Capital
Dallas,
Texas
|
-$38K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$27K |
RDHL Hedge Fund Activity: Q3 2022 in Review
40 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q3 2022, worth a combined $1.46M — down 62% from $3.89M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RDHL and 5 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, adding an estimated $219K. The largest seller was ARK Investment Management, exiting entirely with an estimated $1.17M sold.
- 40 institutional investors held Redhill Biopharma (RDHL) as of Q3 2022, down from 44 in Q2 2022.
- Funds reported $1.46M of Redhill Biopharma stock for Q3 2022, down 62% quarter-over-quarter.
- 5 funds opened new Redhill Biopharma positions in Q3 2022 and 9 closed out, a net change of -4 holders.
- The largest Redhill Biopharma buyer in Q3 2022 was Millennium Management, an estimated $219K added.
- The largest Redhill Biopharma seller in Q3 2022 was ARK Investment Management, an estimated $1.17M sold.
Based on aggregated 13F filings for Q3 2022.